Kahn Brothers Group Inc. purchased a new position in shares of Novartis AG (NYSE:NVS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,386 shares of the company's stock, valued at approximately $2,044,711,000. Novartis makes up 4.1% of Kahn Brothers Group Inc.'s holdings, making the stock its 4th largest holding.
A number of other institutional investors also recently made changes to their positions in NVS. Dearborn Partners LLC acquired a new stake in shares of Novartis during the second quarter valued at $5,021,000. First Bancorp Inc ME purchased a new position in Novartis in the 2nd quarter valued at about $57,000. Pinnacle West Asset Management Inc. acquired a new stake in shares of Novartis during the 2nd quarter worth about $651,000. Somerville Kurt F acquired a new stake in shares of Novartis during the 2nd quarter worth about $1,636,000. Finally, Trust Co. of Vermont purchased a new stake in shares of Novartis during the second quarter worth about $7,282,000. 13.12% of the stock is owned by institutional investors and hedge funds.
Novartis Price Performance
Novartis stock opened at $154.54 on Friday. Novartis AG has a 1 year low of $121.57 and a 1 year high of $170.46. The firm has a 50 day moving average price of $154.94 and a 200 day moving average price of $153.78. The company has a market cap of $294.88 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.70 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.
Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The company had revenue of $14.95 billion for the quarter. Sell-side analysts predict that Novartis AG will post 8.85 earnings per share for the current year.
Analyst Upgrades and Downgrades
NVS has been the subject of a number of analyst reports. Citigroup reissued a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings restated a "buy (b)" rating on shares of Novartis in a research report on Friday, July 24th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Novartis has a consensus rating of "Hold" and an average price target of $141.20.
View Our Latest Stock Report on Novartis
Novartis Company Profile
(
Free Report)
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
